METHYLENE BLUE in the Treatment of Lung Cancer (2018 Sanchala)
2018 Sanchala et al: “Anticancer activity of methylene blue via inhibition of heat shock protein 70”
Heat shock protein 70 (Hsp70) and heat shock protein 90 (Hsp90) chaperones are indispensable to lung cancer cells for their survival and proliferation
“In this study we evaluated and compared anticancer potential of methylene blue (MB) as an Hsp70 inhibitor”
Heat shock proteins are also known as apoptosis inhibitors
Hsp70 over-expression is associated with adverse prognosis and resistance to chemotherapy
Authors tested Human NSCLC Cell line A549 with Methylene Blue (MB) and Novobiocin (NB) a well known Hsp90 inhibitor
Results:
“Treatment with MB demonstrates superior anticancer activity”
“MB demonstrated dose and time-dependent decrease in A549 (lung cancer) cells viability %”
“Treatment with MB induces early apoptosis and demonstrates superior apoptotic activity versus NB”
“Treatment with MB alone significantly inhibits Hsp70”
In vivo: “Mice treated with MB+NB and MB alone demonstrates improvement in lung tumor markers and antioxidant levels in addition to improvement in body weight by treatment with MB alone”
In vivo: “Mice treated with MB and MB+NB resulted in improved lung micro architecture and less proliferative lesions”
CONCLUSION:
“Based on our evidence, methylene blue as an Hsp70 inhibitor is a potent and promising anticancer agent. “
“Methylene blue demonstrated potent and superior (versus Novobiocin) antineoplastic activity in vitro and in vivo.”
[Via: makismd.substack.com]